367 related articles for article (PubMed ID: 22450705)
41. Amyloid-like fibril formation by tachykinin neuropeptides and its relevance to amyloid β-protein aggregation and toxicity.
Singh PK; Maji SK
Cell Biochem Biophys; 2012 Sep; 64(1):29-44. PubMed ID: 22628076
[TBL] [Abstract][Full Text] [Related]
42. Sedimentation velocity analysis of amyloid oligomers and fibrils using fluorescence detection.
Mok YF; Ryan TM; Yang S; Hatters DM; Howlett GJ; Griffin MD
Methods; 2011 May; 54(1):67-75. PubMed ID: 21055469
[TBL] [Abstract][Full Text] [Related]
43. Generation of reactive oxygen species by beta amyloid fibrils and oligomers involves different intra/extracellular pathways.
Cenini G; Cecchi C; Pensalfini A; Bonini SA; Ferrari-Toninelli G; Liguri G; Memo M; Uberti D
Amino Acids; 2010 Apr; 38(4):1101-6. PubMed ID: 19582548
[TBL] [Abstract][Full Text] [Related]
44. An anti-Aβ (amyloid β) single-chain variable fragment prevents amyloid fibril formation and cytotoxicity by withdrawing Aβ oligomers from the amyloid pathway.
Marín-Argany M; Rivera-Hernández G; Martí J; Villegas S
Biochem J; 2011 Jul; 437(1):25-34. PubMed ID: 21501114
[TBL] [Abstract][Full Text] [Related]
45. Globular amyloid beta-peptide oligomer - a homogenous and stable neuropathological protein in Alzheimer's disease.
Barghorn S; Nimmrich V; Striebinger A; Krantz C; Keller P; Janson B; Bahr M; Schmidt M; Bitner RS; Harlan J; Barlow E; Ebert U; Hillen H
J Neurochem; 2005 Nov; 95(3):834-47. PubMed ID: 16135089
[TBL] [Abstract][Full Text] [Related]
46. Membrane lipid composition and its physicochemical properties define cell vulnerability to aberrant protein oligomers.
Evangelisti E; Cecchi C; Cascella R; Sgromo C; Becatti M; Dobson CM; Chiti F; Stefani M
J Cell Sci; 2012 May; 125(Pt 10):2416-27. PubMed ID: 22344258
[TBL] [Abstract][Full Text] [Related]
47. Effect of the surface charge of artificial model membranes on the aggregation of amyloid β-peptide.
Sabaté R; Espargaró A; Barbosa-Barros L; Ventura S; Estelrich J
Biochimie; 2012 Aug; 94(8):1730-8. PubMed ID: 22542639
[TBL] [Abstract][Full Text] [Related]
48. Early mechanisms of amyloid fibril nucleation in model and disease-related proteins.
Morel B; Conejero-Lara F
Biochim Biophys Acta Proteins Proteom; 2019 Nov; 1867(11):140264. PubMed ID: 31437584
[TBL] [Abstract][Full Text] [Related]
49. The role of lipid-protein interactions in amyloid-type protein fibril formation.
Gorbenko GP; Kinnunen PK
Chem Phys Lipids; 2006 Jun; 141(1-2):72-82. PubMed ID: 16569401
[TBL] [Abstract][Full Text] [Related]
50. Biological membranes as protein aggregation matrices and targets of amyloid toxicity.
Bucciantini M; Cecchi C
Methods Mol Biol; 2010; 648():231-43. PubMed ID: 20700716
[TBL] [Abstract][Full Text] [Related]
51. Development of a proteolytically stable retro-inverso peptide inhibitor of beta-amyloid oligomerization as a potential novel treatment for Alzheimer's disease.
Taylor M; Moore S; Mayes J; Parkin E; Beeg M; Canovi M; Gobbi M; Mann DM; Allsop D
Biochemistry; 2010 Apr; 49(15):3261-72. PubMed ID: 20230062
[TBL] [Abstract][Full Text] [Related]
52. Structural, morphological, and functional diversity of amyloid oligomers.
Breydo L; Uversky VN
FEBS Lett; 2015 Sep; 589(19 Pt A):2640-8. PubMed ID: 26188543
[TBL] [Abstract][Full Text] [Related]
53. Structural origin of polymorphism of Alzheimer's amyloid β-fibrils.
Agopian A; Guo Z
Biochem J; 2012 Oct; 447(1):43-50. PubMed ID: 22823461
[TBL] [Abstract][Full Text] [Related]
54. Antiparallel beta-sheet: a signature structure of the oligomeric amyloid beta-peptide.
Cerf E; Sarroukh R; Tamamizu-Kato S; Breydo L; Derclaye S; Dufrêne YF; Narayanaswami V; Goormaghtigh E; Ruysschaert JM; Raussens V
Biochem J; 2009 Jul; 421(3):415-23. PubMed ID: 19435461
[TBL] [Abstract][Full Text] [Related]
55. Structural polymorphism and possible pathways of amyloid fibril formation on the example of insulin protein.
Selivanova OM; Galzitskaya OV
Biochemistry (Mosc); 2012 Nov; 77(11):1237-47. PubMed ID: 23240561
[TBL] [Abstract][Full Text] [Related]
56. A disulfide-linked amyloid-beta peptide dimer forms a protofibril-like oligomer through a distinct pathway from amyloid fibril formation.
Yamaguchi T; Yagi H; Goto Y; Matsuzaki K; Hoshino M
Biochemistry; 2010 Aug; 49(33):7100-7. PubMed ID: 20666485
[TBL] [Abstract][Full Text] [Related]
57. Alzheimer's disease: β-amyloid plaque formation in human brain.
Seeman P; Seeman N
Synapse; 2011 Dec; 65(12):1289-97. PubMed ID: 21633975
[TBL] [Abstract][Full Text] [Related]
58. Dual role of p53 amyloid formation in cancer; loss of function and gain of toxicity.
Lasagna-Reeves CA; Clos AL; Castillo-Carranza D; Sengupta U; Guerrero-Muñoz M; Kelly B; Wagner R; Kayed R
Biochem Biophys Res Commun; 2013 Jan; 430(3):963-8. PubMed ID: 23261448
[TBL] [Abstract][Full Text] [Related]
59. Protein misfolded oligomers: experimental approaches, mechanism of formation, and structure-toxicity relationships.
Bemporad F; Chiti F
Chem Biol; 2012 Mar; 19(3):315-27. PubMed ID: 22444587
[TBL] [Abstract][Full Text] [Related]
60. Structural characterization and biological properties of the amyloidogenic elastin-like peptide (VGGVG)3.
Moscarelli P; Boraldi F; Bochicchio B; Pepe A; Salvi AM; Quaglino D
Matrix Biol; 2014 Jun; 36():15-27. PubMed ID: 24686253
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
